Muangwong Pooriwat, Tungkasamit Tharatorn, Samakgarn Vatanyu, Chumachote Ausareeya, Kittidachanan Kittikun, Chitapanarux Imjai
Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Department of Medical Services, Udon Thani Cancer Hospital, Ministry of Public Health, Udon Thani, Thailand.
PLoS One. 2025 Mar 27;20(3):e0320145. doi: 10.1371/journal.pone.0320145. eCollection 2025.
Immunonutrition (IN) supplements, designed to modulate immune system, may help reduce treatment-related toxicities. This study aimed to evaluate the efficacy of IN in reducing acute oral mucositis (OM) and other side effects in head and neck cancer patients undergoing concurrent chemoradiotherapy (CCRT).
A multicenter, prospective, open-label randomized controlled study was conducted to assess the impact of IN on reducing OM and other side effects in head and neck cancer patients undergoing CCRT. Patients were randomized into either IN or control arms. Those in the IN arm received IN sachets starting one week before radiotherapy until treatment completion, while the control arm received no supplement. Treatment outcomes were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) version 5 and patient-reported outcomes via National Cancer Institute's Patient-Reported Outcomes of CTCAE (NCI-PRO-CTCAE). Mixed-effects logistic regression was performed to analyze outcomes between the groups, adjusting for chemotherapy regimens, while Chi-squared tests were used for group comparisons at specific timepoints.
A total of 87 patients were analyzed with 46 in IN arm and 41 in control arm. Physician evaluations showed similar rates of grade 2 or higher OM, dermatitis, esophagitis, and hematologic toxicities across both arms. Patient-reported outcomes also showed no significant differences in the severity of oral mucositis or its interference with daily activities. A significant reduction of dermatitis was observed at week 3 in the IN arm (9.8% vs. 34.8%, p = 0.03), but this effect was not sustained in later weeks.
IN supplementation during CCRT did not result in statistically significant reductions in acute oral mucositis and other radiation toxicities. Further research with larger sample sizes, compliance monitoring, and optimized supplementation protocols is warranted to better understand the potential benefits of IN.
免疫营养(IN)补充剂旨在调节免疫系统,可能有助于降低与治疗相关的毒性。本研究旨在评估IN在降低接受同步放化疗(CCRT)的头颈癌患者急性口腔黏膜炎(OM)及其他副作用方面的疗效。
开展了一项多中心、前瞻性、开放标签随机对照研究,以评估IN对降低接受CCRT的头颈癌患者OM及其他副作用的影响。患者被随机分为IN组或对照组。IN组患者从放疗前一周开始接受IN小包装产品,直至治疗结束,而对照组不接受补充剂。使用不良事件通用术语标准(CTCAE)第5版评估治疗结果,并通过美国国立癌症研究所的CTCAE患者报告结局(NCI-PRO-CTCAE)评估患者报告的结局。进行混合效应逻辑回归分析两组之间的结局,并对化疗方案进行校正,同时使用卡方检验在特定时间点进行组间比较。
共分析了87例患者,其中IN组46例,对照组41例。医生评估显示,两组2级或更高级别OM、皮炎、食管炎和血液学毒性的发生率相似。患者报告的结局也显示,口腔黏膜炎的严重程度或其对日常活动的干扰无显著差异。在第3周时,IN组的皮炎有显著减少(9.8%对34.8%,p = 0.03),但在随后几周这种效果未持续。
CCRT期间补充IN并未使急性口腔黏膜炎和其他放疗毒性有统计学意义的降低。有必要进行更大样本量、依从性监测和优化补充方案的进一步研究,以更好地了解IN的潜在益处。